7 Results for "

PRYSPRY domain

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "PRYSPRY domain" in MCE Product Catalog:

Cat. No.: HY-170430
CAS No.: 3055558-98-7
Domaines de recherche:  

Cancer

HGC652 is a molecular glue degrader targeting TRIM21 with a TRIM21-dependent nuclear membrane disruption effect. HGC652 binds to the PRY-SPRY domain of TRIM21 with high affinity (Ka=0.061 μM), mediates the interaction between TRIM21 and NUP98, and redirects E3 ligase activity. By triggering the polyubiquitination and proteasomal degradation of nucleoporins (such as NUP155 and GLE1), HGC652 disrupts nuclear membrane integrity, alters nuclear morphology, induces genomic instability, and thereby induces cancer cell death .
loading...
    loading...
Cat. No.: HY-159082
Target:  

Ligands for E3 Ligase

Domaines de recherche:  

Cancer

TRIM7-IN-1 (compound89) is a potent TRIM7 inhibitor with a KD value of 2.6 µM .
loading...
    loading...
Cat. No.: HY-174853
CAS No.: 3111776-36-1
Target:  

E1/E2/E3 Enzyme

Domaines de recherche:  

Others

TRIM25 ligand-1 (Compound 10) is a covalent ligand. TRIM25 ligand-1 can covalently bind to Cys498 in the PRYSPRY domain of TRIM25 and enhance its auto-ubiquitination activity. TRIM25 ligand-1 is selective for TRIM25 in vitro and in live cells .
loading...
    loading...
Cat. No.: HY-169355
CAS No.: 3095569-91-5
Domaines de recherche:  

Inflammation/Immunology Cancer

TrimTAC1 is a TRIM21-based PROTAC degrader targeting BRD4, with a DC50 of 0.649 nM. TrimTAC1 selectively degrades multimeric proteins, including those localized in biomolecular condensates, while exerting no effect on monomeric proteins in the dilute phase. This degradation effect can be blocked by Bortezomib (HY-10227) or TAK-243 (HY-100487). TrimTAC1 can be used in research related to pancreatic cancer and autoimmune diseases .
loading...
    loading...
Cat. No.: HY-W1125585
Domaines de recherche:  

Cancer

PRLX-93936 analog 1 is a TRIM21-targeting cytotoxin. PRLX-93936 analog 1 binds to the TRIM21 PRYSPRY domain, inducing TRIM21-mediated ubiquitination and degradation of nucleoporin proteins. PRLX-93936 analog 1 impairs nuclear trafficking, triggering cell death. PRLX-93936 analog 1 exhibits TRIM21-dependent cytotoxicity, suppressible by TRIM21 ligand HGC1g. PRLX-93936 analog 1 can be used for the research of acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-180548
MRC37 is a high-affinity TRIM21 ligand with a Kd of 0.4 µM. MRC37 targets the IgG Fc-binding pocket in the PRYSPRY domain of TRIM21, mimics the "HHNY" epitope, and inhibits substrate-induced aggregation and activation of TRIM21 via competitive blockade of antibody binding. MRC37 effectively blocks TRIM21-mediated antiviral immunity (such as adenovirus neutralization) and Trim-Away targeted protein degradation without cytotoxicity. MRC37 antagonizes TRIMTAC activity, and its multiple modification sites do not affect target binding, making it suitable as a degrader warhead for research on viral immunity and neurodegenerative diseases such as tauopathies .
loading...
    loading...
Cat. No.: HY-180547
CAS No.: 3070832-68-4
Target:  

PROTACs

Domaines de recherche:  

Others Neurological Disease

MRC71 is a TRIMTAC degrader that recruits endogenous TRIM21 E3 ligase at one end and covalently binds to HaloTag-fusion target proteins at the other end. MRC71 selectively degrades oligomeric CAV1- and Cavin1-mEGFP-Halo, but not monomeric mEGFP-Halo, and exhibits a typical concentration-dependent degradation profile with a hook effect. MRC71 can be used to verify TRIMTAC ternary complex formation and state-selective degradation in cells .
loading...
    loading...